CERVOS KeyPRP receives MDR 2017/745 Certification
A breakthrough that elevates regenerative medicine in Europe—combining gold-standard safety and quality with exclusive distribution through ASPIRE
Regulatory Milestone Achieved
The CERVOS® KeyPRP System has received EU MDR certification, validating its compliance with the European Union’s highest standards for safety, performance, and quality in medical devices.
CERVOS Medical has achieved a major milestone with the EU MDR 2017/745 certification of its CERVOS KeyPRP System, confirming the device’s compliance with the European Union’s highest standards for medical device safety, performance, and quality. This rigorous certification reinforces the system’s credibility in the competitive regenerative medicine field and highlights CERVOS Medical’s dedication to excellence in manufacturing and quality assurance. With CE marking secured, the company is well-positioned to expand its presence across the European market through its exclusive marketing partner, ASPIRE Medical Innovation. The CERVOS KeyPRP System is an advanced platelet separator designed for autologous regenerative procedures such as PRP therapy, bone marrow aspiration, and adipose tissue processing. It enables clinicians to deliver personalized, cell-based treatments with greater precision and efficiency, enhancing healing outcomes in musculoskeletal, orthopedic, and aesthetic applications. Emphasizing safety, sterility, and ease of use, the system meets the growing demand for minimally invasive regenerative solutions. Backed by parent company Ranfac Corp, CERVOS continues to drive innovation in autologous tissue processing, with the EU MDR certification accelerating its path to broader clinical adoption and international impact.
>> Read the News-Release
